EUVIMEDEUVIMED entdecken
Crossref

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients

Claudia Torino iD, Federico Carbone iD, Patrizia Pizzini, Sabrina Mezzatesta, Graziella D'Arrigo, Mercedes Gori, Luca Liberale iD, Margherita Moriero, Cristina Michelauz, Federica Frè, Simone Isoppo, Aurora Gavoci und 8 weitere

European Journal of Clinical Investigation · 2024-09 · 54 (9)

DOI: 10.1111/eci.14235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 11.05.2024. Verfasst von Claudia Torino und 19 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Pisa, Italy. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Renal Dialysis, Cardiovascular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a factor accelerating the degradation of LDL receptors, was associated with a gender‐dependent risk for cardiovascular (CV) events in the general population and with all‐cause and CV mortality in two relatively small studies in black Africans and South Korean haemodialysis patients. The effect modification by gender was untested in these studies.

Methods

The study enrolled 1188 dialysis patients from the Prospective Registry of The Working Group of Epidemiology of Dialysis Region Calabria (PROGREDIRE) cohort. PCSK9 was measured by colorimetric enzyme‐linked immunosorbent assay. The primary outcomes were all‐cause and CV mortality. Statistical analysis included Cox regression analysis and effect modification analysis.

Results

During a median 2.9‐year follow‐up, out of 494 deaths, 278 were CV‐related. In unadjusted analyses, PCSK9 levels correlated with increased all‐cause (HR for1ln unit increase : 1.23, 95% CI 1.06–1.43, p =.008) and CV mortality (HR for1ln unit increase : 1.26, 95% CI 1.03–1.54, p =.03). After multivariate adjustment, these associations were no longer significant (all‐cause mortality, HR for 1 ln unit increase : 1.16, 95% CI .99–1.36, p =.07; CV mortality, HR for1ln unit increase : 1.18, 95% CI .95–1.46, p =.14). However, in fully adjusted interaction analyses, a doubling in the risk of this outcome in women was registered (Women, HR for1ln unit increase : 1.88, 95% CI 1.27–2.78, p =.002; Men, HR for1ln unit increase : 1.07, 95% CI .83–1.38, p =.61; p for effect modification: .02).

Conclusions

PCSK9 levels are unrelated to all‐cause mortality in haemodialysis patients but, like in studies of the general population, independently of other risk factors, entail a doubling in the risk of CV events in women in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9Renal DialysisCardiovascular DiseasesHumansMaleFemaleMiddle AgedAgedProspective StudiesKidney Failure, ChronicProportional Hazards ModelsCause of DeathSex FactorsRisk Factors

Stichwörter der Autor:innen

ESKDPCSK9cardiovascularclinical outcomesdialysis

Substanzen

Proprotein Convertase 9PCSK9 protein, human

Autor:innen und Institutionen

  • Clinical Epidemiology of Renal Disease and Hypertension Unit, Reggio Cal CNR Unit of the Pisa CNR Institute of Clinical Physiology, Pisa, Italy.
  • First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
  • IRCCS Ospedale Policlinico San Martino, Genoa-Italian Cardiovascular Network, Genoa, Italy.
  • CNR-IFC, Rome, Italy.
  • Nephrology, Hypertension and Renal Transplantation Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
  • Renal Research Institute, New York, USA.

ORCID-Profile: Claudia Torino, Federico Carbone, Luca Liberale, Fabrizio Montecucco, Carmine Zoccali

Zitieren

APA

Torino, C., Carbone, F., Pizzini, P., Mezzatesta, S., D'Arrigo, G., Gori, M., Liberale, L., Moriero, M., Michelauz, C., Frè, F., Isoppo, S., Gavoci, A., La Rosa, F., Scuricini, A., Tirandi, A., Ramoni, D., Mallamaci, F., Tripepi, G., Montecucco, F., & Zoccali, C. (2024). Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients. European Journal of Clinical Investigation, 54(9). https://doi.org/10.1111/eci.14235

Vancouver

Torino C, Carbone F, Pizzini P, Mezzatesta S, D'Arrigo G, Gori M, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients. European Journal of Clinical Investigation. 2024;54(9). doi:10.1111/eci.14235

BibTeX
@article{Torino2024,
  author = {Torino, Claudia and Carbone, Federico and Pizzini, Patrizia and Mezzatesta, Sabrina and D'Arrigo, Graziella and Gori, Mercedes and Liberale, Luca and Moriero, Margherita and Michelauz, Cristina and Frè, Federica and Isoppo, Simone and Gavoci, Aurora and La Rosa, Federica and Scuricini, Alessandro and Tirandi, Amedeo and Ramoni, Davide and Mallamaci, Francesca and Tripepi, Giovanni and Montecucco, Fabrizio and Zoccali, Carmine},
  title = {Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  volume = {54},
  number = {9},
  doi = {10.1111/eci.14235}
}
Kostenlos starten →